<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Applied Biomedical Research</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D527967C-F2CF-4E39-928E-B7A6E847C7B1"><gtr:id>D527967C-F2CF-4E39-928E-B7A6E847C7B1</gtr:id><gtr:firstName>Stuart</gtr:firstName><gtr:surname>Bevan</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BF812935-3523-4542-8B74-C43165CBCA00"><gtr:id>BF812935-3523-4542-8B74-C43165CBCA00</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Howell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601043"><gtr:id>3BB850B0-70A9-4BFF-AC6A-0F216D46B893</gtr:id><gtr:title>Translational Research Pilot Scheme</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601043</gtr:grantReference><gtr:abstractText>The UK is very strong in basic biomedical research,but less good in translating the results of this basic research into new information, products or devices which can be used by the pharmaceutical industry to produce new medicines.This pilot scheme tests the idea that skilled and experienced translators who work closely with both scientists and doctors can effectively facilitate this translation process.</gtr:abstractText><gtr:technicalSummary>Effective development of basic science findings to proof of concept and preclinical stages of development is notably difficult to achieve.This pilot scheme aims to test the hypothesis that a skilled and experienced translator working alongside basic scientists can, if appropriately resourced, facilitate this translation process.The pilot will run for 3 years and the outcome will be independently evaluated by MRC.</gtr:technicalSummary><gtr:fund><gtr:end>2011-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>444721</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Devolved DPFS Portfolio</gtr:description><gtr:end>2011-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0900865</gtr:fundingRef><gtr:id>7C01155C-94E7-4F36-8B26-E490F0BE7BA0</gtr:id><gtr:outcomeId>GHnrsLnDRQa0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Importance of HLA epitope matching for transplantation</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>978612EE-0181-404D-823A-3A5D45B35451</gtr:id><gtr:outcomeId>Tk6L5tkY7Fq</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Inhibitors of IgE-receptor interactions have been identified. These are currently being evaluated by Pharma companies for potential licencing</gtr:description><gtr:id>5743F156-76FD-4CB4-BA25-FB1740FB7382</gtr:id><gtr:impact>Small molecule inhibitors of IgE action potentially suitable for clinical development</gtr:impact><gtr:outcomeId>GhUzJxE8m7y</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>IgE-receptor inhibitors</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Inhibitors of IgE-receptor interactions</gtr:description><gtr:id>A14C57CF-043F-4C36-9350-1340A669ECFD</gtr:id><gtr:impact>The compounds are under evaluation by Pharma companies for potential licencing</gtr:impact><gtr:outcomeId>29C48253AB0</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>IgE-receptor inhibitors</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>PCR methodology for HLA epitope matching</gtr:description><gtr:id>DFE1F06E-FEDA-40CC-9E4E-EF7A6BDD902B</gtr:id><gtr:impact>Influenced status of HLA epitope matching and progress towards naming of epitopes</gtr:impact><gtr:outcomeId>AxzsPDp7TUt</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Epitope PCR</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>A7640E22-0A53-445E-9D20-77427F4F9DFD</gtr:id><gtr:title>Total synthesis of (+/-)-aspercyclide A and its C19 methyl ether.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42b9baf75965bce08cbac00451a852fd"><gtr:id>42b9baf75965bce08cbac00451a852fd</gtr:id><gtr:otherNames>Carr JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>KRYJk3pTecr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>777C0DE8-A89D-4CB3-BE5E-5C7F75C4833A</gtr:id><gtr:title>Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor Fc?RI.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/912538b3960e48e1db262c7f0859431b"><gtr:id>912538b3960e48e1db262c7f0859431b</gtr:id><gtr:otherNames>Holdom MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn><gtr:outcomeId>5a32789d5062c0.15055748</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BF73BB6-201E-4930-A853-49EC9443A203</gtr:id><gtr:title>Synthesis of the C19 methyl ether of aspercyclide A via germyl-Stille macrocyclisation and ELISA evaluation of both enantiomers following optical resolution.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42b9baf75965bce08cbac00451a852fd"><gtr:id>42b9baf75965bce08cbac00451a852fd</gtr:id><gtr:otherNames>Carr JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>UttYffPdugN</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601043</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>A056411B-DD7A-4062-BE33-7849FBC9BFA7</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.9  Resources and infrastructure (development of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>